Abstract:The most prevalent physiological effects of ANG II, the main product of the renin-angiotensin system, are mediated by the AT1 receptor, a rhodopsin-like AGPCR. Numerous studies of the cardiovascular effects of synthetic peptide analogs allowed a detailed mapping of ANG II's structural requirements for receptor binding and activation, which were complemented by site-directed mutagenesis studies on the AT1 receptor to investigate the role of its structure in ligand binding, signal transduction, phosphorylation, binding to arrestins, internalization, desensitization, tachyphylaxis, and other properties. The knowledge of the high-resolution structure of rhodopsin allowed homology modeling of the AT1 receptor. The models thus built and mutagenesis data indicate that physiological (agonist binding) or constitutive (mutated receptor) activation may involve different degrees of expansion of the receptor's central cavity. Residues in ANG II structure seem to control these conformational changes and to dictate the type of cytosolic event elicited during the activation. 1) Agonist aromatic residues (Phe8 and Tyr4) favor the coupling to G protein, and 2) absence of these residues can favor a mechanism leading directly to receptor internalization via phosphorylation by specific kinases of the receptor's COOH-terminal Ser and Thr residues, arrestin binding, and clathrin-dependent coated-pit vesicles. On the other hand, the NH2-terminal residues of the agonists ANG II and [Sar1]-ANG II were found to bind by two distinct modes to the AT1 receptor extracellular site flanked by the COOH-terminal segments of the EC-3 loop and the NH2-terminal domain. Since the [Sar1]-ligand is the most potent molecule to trigger tachyphylaxis in AT1 receptors, it was suggested that its corresponding binding mode might be associated with this special condition of receptors.

Characterization of Angiotensin II Antagonism Displayed by Ib, a Novel Nonpeptide Angiotensin AT1 Receptor Antagonist

Antihypertensive Effects of a New Angiotensin Type 1 Receptor Antagonist I B on Rats

[Ca2+]i and PKC-α are involved in the inhibitory effects of Ib, a novel nonpeptide AngiotensinII subtype AT1 receptor antagonist, on AngiotensinII-induced vascular contraction in vitro

[Ca2+](I) And Pkc-Alpha Are Involved In The Inhibitory Effects Of 1b, A Novel Nonpeptide Angiotensinii Subtype At(1) Receptor Antagonist, On Angiotensinii-Induced Vascular Contraction In Vitro

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist

Structural Insights into Ligand Recognition and Activation of Angiotensin Receptors.

Design, Synthesis, and Biological Evaluation of 1,2,4-Triazole Bearing 5-Substituted Biphenyl-2-sulfonamide Derivatives As Potential Antihypertensive Candidates

Effects of a New Angiotensin Type 1 Receptor Antagonist Ib on Isoproterenol-Induced Cardiac Hypertrophy in Rats

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography

Identification of the major metabolites of 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a new angiotensin type 1 receptor antagonist, in rat bile by HPLC-diode array detection-MS and HPLC-MS/MS.

Determination of 5- N -Butyl-4-{4-[2-( 1H -Tetrazole-5-yl)- 1H -Pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)- 3H -1,2,4-triazol-3-one, a New Angiotensin Type 1 Receptor Antagonist in Rat Plasma by LC-ESI-MS: Application to Pharmacokinetic Studies

The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure

Implications of β-Arrestin biased signaling by angiotensin II type 1 receptor for cardiovascular drug discovery and therapeutics

Angiotensin Iv Protects Against Angiotensin Ii-Induced Cardiac Injury Via At4 Receptor

Identification of higenamine as a novel α1 -adrenergic receptor antagonist.

Structural and Functional Analysis of Olmesartan As an Inverse Agonist for Angiotensin Ii Type 1 Receptor

Research and Development of the New Drugs Acting on Angiotensin II Receptor

Angiotensin Ii Type 1 Receptor Antagonists in Animal Models of Vascular, Cardiac, Metabolic and Renal Disease